Back to IPSEYView full pipeline
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
2
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
Drug Information
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Regulatory Approvals
EMA9/19/2024
Kayfanda
Kayfanda is indicated for the treatment of cholestatic pruritus in Alagille syndrome (ALGS) in patients aged 6 months or older (see sections 4.4 and 5.1).
View on EMAEMA7/16/2021
Bylvay
Bylvay is indicated for the treatment of progressive familial intrahepatic cholestasis (PFIC) in patients aged 6 months or older (see sections 4.4 and 5.1).
OrphanAcceleratedPRIME
View on EMADrug Science
Mechanism of action & safety profile
Related Pipeline
ElafibranorPhase 3
Primary Biliary Cholangitis
Lanreotide (Autogel formulation)Phase 3
Acromegaly
Lanreotide Autogel®Phase 3
Acromegaly
Triptorelin pamoate (embonate) saltPhase 3
Advanced Prostate Cancer
lanreotide (Autogel formulation), duration of treatment 24-56 weeks, depending on dose intervalPhase 3
Acromegaly
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts